Bank of Hawaii’s Acadia Pharmaceuticals ACAD Stock Holding History

Bank of Hawaii’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,112	Closed	-$273K	–	262
2020 Q4	$273K	Buy	+5,112	New	+$254K	0.02%	237

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bank of Hawaii's ACAD Position: Q1 2021 in Review

Bank of Hawaii sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 5,112 shares — an estimated $273K sold.

Bank of Hawaii first reported a position in ACAD in Q4 2020 and held it in 1 quarter. The position peaked at $273K in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Bank of Hawaii reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Bank of Hawaii sold 5,112 Acadia Pharmaceuticals shares in Q1 2021, an estimated $273K.
Bank of Hawaii first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Bank of Hawaii's Acadia Pharmaceuticals position peaked at $273K in Q4 2020.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Bank of Hawaii's 13F filing for Q1 2021, filed 13 May 2021.